Patient characteristics, treatment patterns and outcomes of advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations: A non-interventional Retrospective Medical Chart Review in Spain.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
TAKEDA FARMACEUTICA ESPAÑA S.A
Cita
Patient characteristics, treatment patterns and outcomes of advanced Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations: A non-interventional Retrospective Medical Chart Review in Spain. (TAK-788-5009). TAKEDA FARMACEUTICA ESPAÑA S.A. 2022-2023. IP:ÓSCAR JOSÉ JUAN VIDAL.
Portal de investigación